Hipk2 Represses Beta-Catenin-Mediated Transcription, Epidermal Stem Cell Expansion, and Skin Tumorigenesis

Guangwei Wei,Stephen Ku,Gene K. Ma,Shin'ichi Saito,Amy A. Tang,Jiasheng Zhang,Jian-Hua Mao,Ettore Appella,Allan Balmain,Eric J. Huang

DOI: https://doi.org/10.1073/pnas.0703213104

IF: 11.1

2007-01-01

Proceedings of the National Academy of Sciences

Abstract:Transcriptional control by β-catenin and lymphoid enhancer-binding factor 1 (LEF1)/T cell factor regulates proliferation in stem cells and tumorigenesis. Here we provide evidence that transcriptional co repressor homeodomain interacting protein kinase 2 (HIPK2) controls the number of stem and progenitor cells in the skin and the susceptibility to develop squamous cell carcinoma. Loss of HIPK2 leads to increased proliferative potential, more rapid G 1 –S transition in cell cycle, and expansion of the epidermal stem cell compartment. Among the critical regulators of G 1 –S transition in the cell cycle, only cyclin D1 is selectively up-regulated in cells lacking HIPK2. Conversely, overexpression of HIPK2 suppresses LEF1/β-catenin-mediated transcriptional activation of cyclin D1 expression. However, deletion of the C-terminal YH domain of HIPK2 completely abolishes its ability to recruit another transcriptional corepressor CtBP and suppress LEF1/β-catenin-mediated transcription. To determine whether loss of HIPK2 leads to increased susceptibility to tumorigenesis, we treat wild-type, Hipk2 +/− , and Hipk2 −/− mice with the two-stage carcinogenesis protocol. Our results indicate that more skin tumors are induced in Hipk2 +/− and Hipk2 −/− mutants, with most of the tumors showing shortened incubation time and malignant progression. Together, our results indicate that HIPK2 is a tumor suppressor that controls proliferation by antagonizing LEF1/β-catenin-mediated transcription. Loss of HIPK2 synergizes with activation of H-ras to induce tumorigenesis.